Gerresheimer AG
Gerresheimer AG (GRRMF) Stock Competitors & Peer Comparison
See (GRRMF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRRMF | $21.66 | +0.00% | 748.1M | 27.42 | $0.79 | +0.21% |
| SRTOY | $18.34 | -0.86% | 181B | 60.00 | $0.31 | +0.42% |
| ESLOF | $233.82 | -4.49% | 108.3B | 40.74 | $5.74 | +1.92% |
| ESLOY | $116.69 | -3.55% | 108.1B | 40.53 | $2.88 | +1.92% |
| MECNY | $88.63 | +0.00% | 107.5B | N/A | N/A | N/A |
| SOAGY | $47.91 | -2.84% | 70B | 92.12 | $0.52 | +0.33% |
| HOCPF | $187.00 | +0.00% | 63.2B | 48.57 | $3.85 | +0.86% |
| HOCPY | $172.87 | +0.54% | 58.4B | 45.21 | $3.82 | +0.74% |
| RSMDF | $21.96 | +0.00% | 32B | 22.64 | $0.97 | +1.01% |
| TRUMF | $13.79 | +11.48% | 20.3B | 24.62 | $0.56 | +1.36% |
Stock Comparison
GRRMF vs SRTOY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SRTOY has a market cap of 181B. Regarding current trading prices, GRRMF is priced at $21.66, while SRTOY trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SRTOY's P/E ratio is 60.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SRTOY's competition here
GRRMF vs ESLOF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ESLOF has a market cap of 108.3B. Regarding current trading prices, GRRMF is priced at $21.66, while ESLOF trades at $233.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ESLOF's P/E ratio is 40.74. In terms of profitability, GRRMF's ROE is +0.02%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ESLOF's competition here
GRRMF vs ESLOY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ESLOY has a market cap of 108.1B. Regarding current trading prices, GRRMF is priced at $21.66, while ESLOY trades at $116.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ESLOY's P/E ratio is 40.53. In terms of profitability, GRRMF's ROE is +0.02%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ESLOY's competition here
GRRMF vs MECNY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, MECNY has a market cap of 107.5B. Regarding current trading prices, GRRMF is priced at $21.66, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas MECNY's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, GRRMF and MECNY have similar daily volatility (0.00).Check MECNY's competition here
GRRMF vs SOAGY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SOAGY has a market cap of 70B. Regarding current trading prices, GRRMF is priced at $21.66, while SOAGY trades at $47.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SOAGY's P/E ratio is 92.12. In terms of profitability, GRRMF's ROE is +0.02%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SOAGY's competition here
GRRMF vs HOCPF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, HOCPF has a market cap of 63.2B. Regarding current trading prices, GRRMF is priced at $21.66, while HOCPF trades at $187.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas HOCPF's P/E ratio is 48.57. In terms of profitability, GRRMF's ROE is +0.02%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, GRRMF and HOCPF have similar daily volatility (0.00).Check HOCPF's competition here
GRRMF vs HOCPY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, HOCPY has a market cap of 58.4B. Regarding current trading prices, GRRMF is priced at $21.66, while HOCPY trades at $172.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas HOCPY's P/E ratio is 45.21. In terms of profitability, GRRMF's ROE is +0.02%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, GRRMF is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check HOCPY's competition here
GRRMF vs RSMDF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, RSMDF has a market cap of 32B. Regarding current trading prices, GRRMF is priced at $21.66, while RSMDF trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas RSMDF's P/E ratio is 22.64. In terms of profitability, GRRMF's ROE is +0.02%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, GRRMF is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check RSMDF's competition here
GRRMF vs TRUMF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TRUMF has a market cap of 20.3B. Regarding current trading prices, GRRMF is priced at $21.66, while TRUMF trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TRUMF's P/E ratio is 24.62. In terms of profitability, GRRMF's ROE is +0.02%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, GRRMF is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TRUMF's competition here
GRRMF vs TRUMY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TRUMY has a market cap of 19B. Regarding current trading prices, GRRMF is priced at $21.66, while TRUMY trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TRUMY's P/E ratio is 23.02. In terms of profitability, GRRMF's ROE is +0.02%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, GRRMF is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TRUMY's competition here
GRRMF vs SUVPF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SUVPF has a market cap of 18.7B. Regarding current trading prices, GRRMF is priced at $21.66, while SUVPF trades at $271.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SUVPF's P/E ratio is 104.26. In terms of profitability, GRRMF's ROE is +0.02%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SUVPF's competition here
GRRMF vs SDMHF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SDMHF has a market cap of 18B. Regarding current trading prices, GRRMF is priced at $21.66, while SDMHF trades at $185.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SDMHF's P/E ratio is 58.54. In terms of profitability, GRRMF's ROE is +0.02%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, GRRMF and SDMHF have similar daily volatility (0.00).Check SDMHF's competition here
GRRMF vs SAUHY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SAUHY has a market cap of 16.4B. Regarding current trading prices, GRRMF is priced at $21.66, while SAUHY trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SAUHY's P/E ratio is 35.45. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, GRRMF is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SAUHY's competition here
GRRMF vs SAUHF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SAUHF has a market cap of 16.3B. Regarding current trading prices, GRRMF is priced at $21.66, while SAUHF trades at $101.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SAUHF's P/E ratio is 35.52. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, GRRMF and SAUHF have similar daily volatility (0.00).Check SAUHF's competition here
GRRMF vs SARTF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SARTF has a market cap of 15.6B. Regarding current trading prices, GRRMF is priced at $21.66, while SARTF trades at $226.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SARTF's P/E ratio is 87.05. In terms of profitability, GRRMF's ROE is +0.02%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SARTF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SARTF's competition here
GRRMF vs CLPBY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CLPBY has a market cap of 15.6B. Regarding current trading prices, GRRMF is priced at $21.66, while CLPBY trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CLPBY's P/E ratio is 25.59. In terms of profitability, GRRMF's ROE is +0.02%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, GRRMF is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CLPBY's competition here
GRRMF vs CLPBF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CLPBF has a market cap of 14.5B. Regarding current trading prices, GRRMF is priced at $21.66, while CLPBF trades at $69.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CLPBF's P/E ratio is 25.07. In terms of profitability, GRRMF's ROE is +0.02%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, GRRMF and CLPBF have similar daily volatility (0.00).Check CLPBF's competition here
GRRMF vs SSSGY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SSSGY has a market cap of 14.5B. Regarding current trading prices, GRRMF is priced at $21.66, while SSSGY trades at $41.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SSSGY's P/E ratio is 80.59. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SSSGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SSSGY's competition here
GRRMF vs FSPKF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, FSPKF has a market cap of 13.1B. Regarding current trading prices, GRRMF is priced at $21.66, while FSPKF trades at $22.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas FSPKF's P/E ratio is 50.70. In terms of profitability, GRRMF's ROE is +0.02%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, GRRMF and FSPKF have similar daily volatility (0.00).Check FSPKF's competition here
GRRMF vs OCPNF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, OCPNF has a market cap of 9B. Regarding current trading prices, GRRMF is priced at $21.66, while OCPNF trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas OCPNF's P/E ratio is 14.93. In terms of profitability, GRRMF's ROE is +0.02%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, GRRMF is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check OCPNF's competition here
GRRMF vs CNVVF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CNVVF has a market cap of 6.6B. Regarding current trading prices, GRRMF is priced at $21.66, while CNVVF trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CNVVF's P/E ratio is 37.78. In terms of profitability, GRRMF's ROE is +0.02%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, GRRMF is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CNVVF's competition here
GRRMF vs CNVVY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CNVVY has a market cap of 6.1B. Regarding current trading prices, GRRMF is priced at $21.66, while CNVVY trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CNVVY's P/E ratio is 36.86. In terms of profitability, GRRMF's ROE is +0.02%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, GRRMF is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CNVVY's competition here
GRRMF vs SSMXF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SSMXF has a market cap of 5.6B. Regarding current trading prices, GRRMF is priced at $21.66, while SSMXF trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SSMXF's P/E ratio is 19.15. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, GRRMF and SSMXF have similar daily volatility (0.00).Check SSMXF's competition here
GRRMF vs AHICF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, AHICF has a market cap of 5.4B. Regarding current trading prices, GRRMF is priced at $21.66, while AHICF trades at $20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas AHICF's P/E ratio is 48.50. In terms of profitability, GRRMF's ROE is +0.02%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, GRRMF is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check AHICF's competition here
GRRMF vs SSMXY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SSMXY has a market cap of 5.4B. Regarding current trading prices, GRRMF is priced at $21.66, while SSMXY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SSMXY's P/E ratio is 19.27. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, GRRMF is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SSMXY's competition here
GRRMF vs YPHDF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, YPHDF has a market cap of 5.2B. Regarding current trading prices, GRRMF is priced at $21.66, while YPHDF trades at $381.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas YPHDF's P/E ratio is 21.01. In terms of profitability, GRRMF's ROE is +0.02%, compared to YPHDF's ROE of +0.30%. Regarding short-term risk, GRRMF is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check YPHDF's competition here
GRRMF vs ADDLF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, GRRMF is priced at $21.66, while ADDLF trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, GRRMF's ROE is +0.02%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, GRRMF is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ADDLF's competition here
GRRMF vs FLMNF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, FLMNF has a market cap of 4.4B. Regarding current trading prices, GRRMF is priced at $21.66, while FLMNF trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas FLMNF's P/E ratio is 20.97. In terms of profitability, GRRMF's ROE is +0.02%, compared to FLMNF's ROE of +0.20%. Regarding short-term risk, GRRMF is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check FLMNF's competition here
GRRMF vs FLMNY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, GRRMF is priced at $21.66, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas FLMNY's P/E ratio is 19.87. In terms of profitability, GRRMF's ROE is +0.02%, compared to FLMNY's ROE of +0.20%. Regarding short-term risk, GRRMF is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check FLMNY's competition here
GRRMF vs ANSLF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ANSLF has a market cap of 3.3B. Regarding current trading prices, GRRMF is priced at $21.66, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, GRRMF's ROE is +0.02%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, GRRMF and ANSLF have similar daily volatility (0.00).Check ANSLF's competition here
GRRMF vs SHWGF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SHWGF has a market cap of 3.3B. Regarding current trading prices, GRRMF is priced at $21.66, while SHWGF trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SHWGF's P/E ratio is 12.17. In terms of profitability, GRRMF's ROE is +0.02%, compared to SHWGF's ROE of +0.08%. Regarding short-term risk, GRRMF and SHWGF have similar daily volatility (0.00).Check SHWGF's competition here
GRRMF vs ANSLY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, GRRMF is priced at $21.66, while ANSLY trades at $84.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ANSLY's P/E ratio is 22.63. In terms of profitability, GRRMF's ROE is +0.02%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ANSLY's competition here
GRRMF vs SHWGY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SHWGY has a market cap of 2.9B. Regarding current trading prices, GRRMF is priced at $21.66, while SHWGY trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SHWGY's P/E ratio is 10.20. In terms of profitability, GRRMF's ROE is +0.02%, compared to SHWGY's ROE of +0.08%. Regarding short-term risk, GRRMF and SHWGY have similar daily volatility (0.00).Check SHWGY's competition here
GRRMF vs CZMWF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CZMWF has a market cap of 2.6B. Regarding current trading prices, GRRMF is priced at $21.66, while CZMWF trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CZMWF's P/E ratio is 16.04. In terms of profitability, GRRMF's ROE is +0.02%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CZMWF's competition here
GRRMF vs CZMWY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CZMWY has a market cap of 2.4B. Regarding current trading prices, GRRMF is priced at $21.66, while CZMWY trades at $26.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CZMWY's P/E ratio is 14.62. In terms of profitability, GRRMF's ROE is +0.02%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CZMWY's competition here
GRRMF vs TCGGY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, GRRMF is priced at $21.66, while TCGGY trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, GRRMF's ROE is +0.02%, compared to TCGGY's ROE of +0.05%. Regarding short-term risk, GRRMF is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TCGGY's competition here
GRRMF vs EKTAF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, EKTAF has a market cap of 2.3B. Regarding current trading prices, GRRMF is priced at $21.66, while EKTAF trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas EKTAF's P/E ratio is -620.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to EKTAF's ROE of -0.00%. Regarding short-term risk, GRRMF and EKTAF have similar daily volatility (0.00).Check EKTAF's competition here
GRRMF vs EKTAY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, EKTAY has a market cap of 2.2B. Regarding current trading prices, GRRMF is priced at $21.66, while EKTAY trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas EKTAY's P/E ratio is -588.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, GRRMF is less volatile compared to EKTAY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check EKTAY's competition here
GRRMF vs TCHBF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TCHBF has a market cap of 2B. Regarding current trading prices, GRRMF is priced at $21.66, while TCHBF trades at $156.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TCHBF's P/E ratio is 24.54. In terms of profitability, GRRMF's ROE is +0.02%, compared to TCHBF's ROE of +0.05%. Regarding short-term risk, GRRMF and TCHBF have similar daily volatility (0.00).Check TCHBF's competition here
GRRMF vs NPRRF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, GRRMF is priced at $21.66, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas NPRRF's P/E ratio is 26.92. In terms of profitability, GRRMF's ROE is +0.02%, compared to NPRRF's ROE of N/A. Regarding short-term risk, GRRMF is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check NPRRF's competition here
GRRMF vs BOEUF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, BOEUF has a market cap of 1.5B. Regarding current trading prices, GRRMF is priced at $21.66, while BOEUF trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas BOEUF's P/E ratio is 98.10. In terms of profitability, GRRMF's ROE is +0.02%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, GRRMF is less volatile compared to BOEUF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check BOEUF's competition here
GRRMF vs TGLVY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TGLVY has a market cap of 1.3B. Regarding current trading prices, GRRMF is priced at $21.66, while TGLVY trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TGLVY's P/E ratio is 31.51. In terms of profitability, GRRMF's ROE is +0.02%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, GRRMF is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TGLVY's competition here
GRRMF vs SAFLY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SAFLY has a market cap of 1.2B. Regarding current trading prices, GRRMF is priced at $21.66, while SAFLY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SAFLY's P/E ratio is 15.38. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAFLY's ROE of +0.11%. Regarding short-term risk, GRRMF and SAFLY have similar daily volatility (0.00).Check SAFLY's competition here
GRRMF vs BITGF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, GRRMF is priced at $21.66, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas BITGF's P/E ratio is 45.50. In terms of profitability, GRRMF's ROE is +0.02%, compared to BITGF's ROE of +0.05%. Regarding short-term risk, GRRMF is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check BITGF's competition here
GRRMF vs PBHDF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, GRRMF is priced at $21.66, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, GRRMF's ROE is +0.02%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, GRRMF and PBHDF have similar daily volatility (0.00).Check PBHDF's competition here
GRRMF vs TDVXF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TDVXF has a market cap of 912M. Regarding current trading prices, GRRMF is priced at $21.66, while TDVXF trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TDVXF's P/E ratio is 50.82. In terms of profitability, GRRMF's ROE is +0.02%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, GRRMF is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TDVXF's competition here
GRRMF vs SAFLF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SAFLF has a market cap of 906.4M. Regarding current trading prices, GRRMF is priced at $21.66, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SAFLF's P/E ratio is 17.77. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAFLF's ROE of +0.11%. Regarding short-term risk, GRRMF and SAFLF have similar daily volatility (0.00).Check SAFLF's competition here
GRRMF vs KSRBF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, GRRMF is priced at $21.66, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, GRRMF's ROE is +0.02%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, GRRMF and KSRBF have similar daily volatility (0.00).Check KSRBF's competition here
GRRMF vs HGYMF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, GRRMF is priced at $21.66, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, GRRMF's ROE is +0.02%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, GRRMF is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check HGYMF's competition here
GRRMF vs NNCSF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, NNCSF has a market cap of 664.3M. Regarding current trading prices, GRRMF is priced at $21.66, while NNCSF trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas NNCSF's P/E ratio is 43.80. In terms of profitability, GRRMF's ROE is +0.02%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, GRRMF and NNCSF have similar daily volatility (0.00).Check NNCSF's competition here
GRRMF vs JNDOF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, GRRMF is priced at $21.66, while JNDOF trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, GRRMF's ROE is +0.02%, compared to JNDOF's ROE of +0.29%. Regarding short-term risk, GRRMF and JNDOF have similar daily volatility (0.00).Check JNDOF's competition here
GRRMF vs SPMXF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, GRRMF is priced at $21.66, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, GRRMF is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SPMXF's competition here
GRRMF vs CLHLF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, GRRMF is priced at $21.66, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, GRRMF's ROE is +0.02%, compared to CLHLF's ROE of +0.14%. Regarding short-term risk, GRRMF and CLHLF have similar daily volatility (0.00).Check CLHLF's competition here
GRRMF vs TSNLF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TSNLF has a market cap of 287.6M. Regarding current trading prices, GRRMF is priced at $21.66, while TSNLF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TSNLF's P/E ratio is 27.27. In terms of profitability, GRRMF's ROE is +0.02%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, GRRMF is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TSNLF's competition here
GRRMF vs GUERF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, GRRMF is priced at $21.66, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas GUERF's P/E ratio is 8.19. In terms of profitability, GRRMF's ROE is +0.02%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, GRRMF and GUERF have similar daily volatility (0.00).Check GUERF's competition here
GRRMF vs OPSSF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, GRRMF is priced at $21.66, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, GRRMF's ROE is +0.02%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, GRRMF is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check OPSSF's competition here
GRRMF vs EEOIF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, GRRMF is priced at $21.66, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, GRRMF's ROE is +0.02%, compared to EEOIF's ROE of N/A. Regarding short-term risk, GRRMF and EEOIF have similar daily volatility (0.00).Check EEOIF's competition here
GRRMF vs OTCFF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, OTCFF has a market cap of 16.1M. Regarding current trading prices, GRRMF is priced at $21.66, while OTCFF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas OTCFF's P/E ratio is -10.14. In terms of profitability, GRRMF's ROE is +0.02%, compared to OTCFF's ROE of +1.24%. Regarding short-term risk, GRRMF and OTCFF have similar daily volatility (0.00).Check OTCFF's competition here
GRRMF vs UEEC Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, UEEC has a market cap of 15M. Regarding current trading prices, GRRMF is priced at $21.66, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas UEEC's P/E ratio is -2.90. In terms of profitability, GRRMF's ROE is +0.02%, compared to UEEC's ROE of +1.00%. Regarding short-term risk, GRRMF is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check UEEC's competition here
GRRMF vs BLMHF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, GRRMF is priced at $21.66, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, GRRMF's ROE is +0.02%, compared to BLMHF's ROE of N/A. Regarding short-term risk, GRRMF and BLMHF have similar daily volatility (0.00).Check BLMHF's competition here
GRRMF vs PXMVF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, GRRMF is priced at $21.66, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, GRRMF's ROE is +0.02%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, GRRMF is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check PXMVF's competition here
GRRMF vs CBSC Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, GRRMF is priced at $21.66, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CBSC's P/E ratio is -4.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to CBSC's ROE of +0.93%. Regarding short-term risk, GRRMF and CBSC have similar daily volatility (0.00).Check CBSC's competition here
GRRMF vs MCDA Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, GRRMF is priced at $21.66, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas MCDA's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MCDA's ROE of N/A. Regarding short-term risk, GRRMF and MCDA have similar daily volatility (0.00).Check MCDA's competition here
GRRMF vs GVDI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, GRRMF is priced at $21.66, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas GVDI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, GRRMF and GVDI have similar daily volatility (0.00).Check GVDI's competition here
GRRMF vs RSCF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, RSCF has a market cap of 4M. Regarding current trading prices, GRRMF is priced at $21.66, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas RSCF's P/E ratio is -4.66. In terms of profitability, GRRMF's ROE is +0.02%, compared to RSCF's ROE of +0.03%. Regarding short-term risk, GRRMF is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check RSCF's competition here
GRRMF vs NSTGQ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, GRRMF is priced at $21.66, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, GRRMF is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check NSTGQ's competition here
GRRMF vs TUTH Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TUTH has a market cap of 3M. Regarding current trading prices, GRRMF is priced at $21.66, while TUTH trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TUTH's P/E ratio is -1.18. In terms of profitability, GRRMF's ROE is +0.02%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, GRRMF and TUTH have similar daily volatility (0.00).Check TUTH's competition here
GRRMF vs ECIA Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ECIA has a market cap of 1.9M. Regarding current trading prices, GRRMF is priced at $21.66, while ECIA trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ECIA's P/E ratio is -5.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, GRRMF is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ECIA's competition here
GRRMF vs YBGJ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, YBGJ has a market cap of 1.8M. Regarding current trading prices, GRRMF is priced at $21.66, while YBGJ trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas YBGJ's P/E ratio is -0.75. In terms of profitability, GRRMF's ROE is +0.02%, compared to YBGJ's ROE of +0.39%. Regarding short-term risk, GRRMF is less volatile compared to YBGJ. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check YBGJ's competition here
GRRMF vs OJSY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, GRRMF is priced at $21.66, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas OJSY's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to OJSY's ROE of N/A. Regarding short-term risk, GRRMF and OJSY have similar daily volatility (0.00).Check OJSY's competition here
GRRMF vs PDMI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, GRRMF is priced at $21.66, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas PDMI's P/E ratio is -0.01. In terms of profitability, GRRMF's ROE is +0.02%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, GRRMF and PDMI have similar daily volatility (0.00).Check PDMI's competition here
GRRMF vs WHSI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, GRRMF is priced at $21.66, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas WHSI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, GRRMF and WHSI have similar daily volatility (0.00).Check WHSI's competition here
GRRMF vs BLFE Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, GRRMF is priced at $21.66, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas BLFE's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, GRRMF and BLFE have similar daily volatility (0.00).Check BLFE's competition here
GRRMF vs QTXB Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, GRRMF is priced at $21.66, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas QTXB's P/E ratio is -0.05. In terms of profitability, GRRMF's ROE is +0.02%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, GRRMF is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check QTXB's competition here
GRRMF vs IMTH Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, GRRMF is priced at $21.66, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas IMTH's P/E ratio is -0.03. In terms of profitability, GRRMF's ROE is +0.02%, compared to IMTH's ROE of -0.32%. Regarding short-term risk, GRRMF is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check IMTH's competition here
GRRMF vs LANZ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, GRRMF is priced at $21.66, while LANZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas LANZ's P/E ratio is 2.70. In terms of profitability, GRRMF's ROE is +0.02%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, GRRMF is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check LANZ's competition here
GRRMF vs CEOS Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, CEOS has a market cap of 35.9K. Regarding current trading prices, GRRMF is priced at $21.66, while CEOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas CEOS's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to CEOS's ROE of +0.40%. Regarding short-term risk, GRRMF is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CEOS's competition here
GRRMF vs GMVDF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, GRRMF is priced at $21.66, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas GMVDF's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, GRRMF and GMVDF have similar daily volatility (0.00).Check GMVDF's competition here
GRRMF vs REMI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, REMI has a market cap of 14K. Regarding current trading prices, GRRMF is priced at $21.66, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas REMI's P/E ratio is -0.07. In terms of profitability, GRRMF's ROE is +0.02%, compared to REMI's ROE of -0.11%. Regarding short-term risk, GRRMF is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check REMI's competition here
GRRMF vs SDCCQ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, GRRMF is priced at $21.66, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, GRRMF and SDCCQ have similar daily volatility (0.00).Check SDCCQ's competition here
GRRMF vs MDIT Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, GRRMF is priced at $21.66, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas MDIT's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, GRRMF and MDIT have similar daily volatility (0.00).Check MDIT's competition here
GRRMF vs ASFX Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ASFX has a market cap of 7K. Regarding current trading prices, GRRMF is priced at $21.66, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ASFX's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, GRRMF is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ASFX's competition here
GRRMF vs DGEN Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, GRRMF is priced at $21.66, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas DGEN's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, GRRMF and DGEN have similar daily volatility (0.00).Check DGEN's competition here
GRRMF vs SVSO Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, GRRMF is priced at $21.66, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SVSO's P/E ratio is -0.01. In terms of profitability, GRRMF's ROE is +0.02%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, GRRMF and SVSO have similar daily volatility (0.00).Check SVSO's competition here
GRRMF vs LFPI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, GRRMF is priced at $21.66, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas LFPI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, GRRMF is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check LFPI's competition here
GRRMF vs INND Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, INND has a market cap of 1.8K. Regarding current trading prices, GRRMF is priced at $21.66, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas INND's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to INND's ROE of +0.12%. Regarding short-term risk, GRRMF is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check INND's competition here
GRRMF vs SEYE Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, GRRMF is priced at $21.66, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SEYE's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SEYE's ROE of N/A. Regarding short-term risk, GRRMF and SEYE have similar daily volatility (0.00).Check SEYE's competition here
GRRMF vs BGMD Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, GRRMF is priced at $21.66, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas BGMD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, GRRMF and BGMD have similar daily volatility (0.00).Check BGMD's competition here
GRRMF vs ADLI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, GRRMF is priced at $21.66, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas ADLI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, GRRMF is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ADLI's competition here
GRRMF vs VSMD Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, VSMD has a market cap of 802. Regarding current trading prices, GRRMF is priced at $21.66, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas VSMD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, GRRMF is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check VSMD's competition here
GRRMF vs TEVNF Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, GRRMF is priced at $21.66, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas TEVNF's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, GRRMF is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TEVNF's competition here
GRRMF vs HRAL Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, HRAL has a market cap of 396. Regarding current trading prices, GRRMF is priced at $21.66, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas HRAL's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to HRAL's ROE of +0.18%. Regarding short-term risk, GRRMF and HRAL have similar daily volatility (0.00).Check HRAL's competition here
GRRMF vs MICRD Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, MICRD has a market cap of 317. Regarding current trading prices, GRRMF is priced at $21.66, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas MICRD's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, GRRMF and MICRD have similar daily volatility (0.00).Check MICRD's competition here
GRRMF vs RGBOQ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, GRRMF is priced at $21.66, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, GRRMF and RGBOQ have similar daily volatility (0.00).Check RGBOQ's competition here
GRRMF vs SECI Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, SECI has a market cap of 31. Regarding current trading prices, GRRMF is priced at $21.66, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas SECI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SECI's ROE of -0.00%. Regarding short-term risk, GRRMF and SECI have similar daily volatility (0.00).Check SECI's competition here
GRRMF vs VTEQ Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, GRRMF is priced at $21.66, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to VTEQ's ROE of N/A. Regarding short-term risk, GRRMF and VTEQ have similar daily volatility (0.00).Check VTEQ's competition here
GRRMF vs MEDVD Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, GRRMF is priced at $21.66, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas MEDVD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MEDVD's ROE of N/A. Regarding short-term risk, GRRMF and MEDVD have similar daily volatility (0.00).Check MEDVD's competition here
GRRMF vs OCPNY Comparison March 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 748.1M. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, GRRMF is priced at $21.66, while OCPNY trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 27.42, whereas OCPNY's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, GRRMF and OCPNY have similar daily volatility (0.00).Check OCPNY's competition here